# Real-life Treatment Outcomes of Ravulizumab in PNH

> **NCT06633536** · — · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 64 (actual)

## Conditions studied

- Paroxysmal Nocturnal Haemoglobinuria

## Interventions

- **DRUG:** Ravulizumab

## Key facts

- **NCT ID:** NCT06633536
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-02-06
- **Primary completion:** 2028-08-01
- **Final completion:** 2028-08-01
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06633536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06633536, "Real-life Treatment Outcomes of Ravulizumab in PNH". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT06633536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*